A Leading Outsourcing Partner to the pharmaceutical industry
Welcome to Dishman Carbogen Amcis Ltd!
We are a global outsourcing partner for pharmaceutical companies, offering a portfolio of products and development, scale-up and manufacturing services. The Dishman Group continually invests in the pharmaceutical industry, ensuring our businesses can provide pharmaceutical customers with high-value, high-quality products and services today and in the future. Our focus is to add value to the global pharmaceutical industry by serving as a reliable partner. We strongly believe that our business is successful only when our customers are successful.
Our Mission
The mission of Dishman Carbogen Amcis Ltd and its fundamental purpose is to offer support and assistance to people across the world suffering from illness and disease, striving to ensure that this is completed efficiently, comprehensively, and effectively.
Latest News
-
News
Dishman Carbogen Amcis Ltd receives 'Choose France - Best Indian Investment in France' award from the Indo French Chamber of Commerce and Industry (IFFCI)
NEW DELHI, India, (April 18, 2024) – Dishman Carbogen Amcis Ltd received the Choose France-Best Indian Investment in France award by the Indo French Chamber of Commerce & Industry in partnership with Business France India, at the sixth flagship event of the Indo-French Business Awards (IFBA) and Grand Prix VIE, in New Delhi. His Excellency Mr. Thierry Mathou, Ambassador of France presented the award which recognises Dishman’s investment in a new...
-
News
Dishman Carbogen Amcis Ltd granted CEP by EDQM and EUDRA GMP Certification by the Italian Medicines Agency
Gujarat, INDIA (January 2024) – Ahmedabad-based Dishman Carbogen Amcis Ltd (DCAL), a pharmaceutical API manufacturing and drug development company receives the CEP certification by the EDQM and the EUDRA GMP by the Italian...
-
News
Dishman Carbogen Amcis Ltd awarded Certification of GMP Compliance by Japan’s Health Authority
Gujarat, India - After a successful on-site inspection, Ahmedabad-based Dishman Carbogen Amcis Ltd (DCAL), receives the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) certification.
DCAL’s drug substances manufacturing facility located in Bavla, underwent an inspection by the Japanese Health Authority. We are glad to announce that the inspection ended satisfactorily, and no major or critical observations...
-
News
Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on Clinical Research Study that reveals positive response in vitamin D deficiency/insufficiency in patients with COVID-19
Ahmedabad, India (December 9th, 2021) — Dishman Carbogen Amcis Ltd, a global outsourcing partner for the pharmaceutical industry, welcomes the results of a new Clinical Research Study which shows that oral 25-Hydroxyvitamin D3 (Calcifediol) was able to correct vitamin D deficiency/insufficiency in patients with COVID-19 and that it resulted in improved immune function by increasing blood...
-
News
Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on study that uncovers treatment for vitamin D deficiency
Ahmedabad, India (May 21th, 2021) — India-based Dishman Carbogen Amcis Ltd, a global outsourcing partner for the pharmaceutical industry, welcomes the results of a new study that provides critical insights into the treatment of vitamin D deficiency in obesity and in fat malabsorption syndromes. The research was conducted by Boston University School of Medicine and supported in part by a grant from Dishman Carbogen Amcis Ltd’s wholly-owned...
-
News
CARBOGEN AMCIS announces major investments of more than CHF 100 million in Switzerland and France
BUBENDORF, Switzerland (August 17, 2020) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today new expansion plans in Switzerland and France.
CARBOGEN AMCIS announces two major expansion projects that will increase manufacturing capacity to better meet the demands of the current market and its customers. The new facilities, located in Switzerland and France, will...
Upcoming events
-
CPhI Japan 2025
CPhI Japan 2025, Tokyo
Leader in API , CRAMS, Formulation
Dishman Carbogen Amcis Ltd - A Leader in API, CRAMS, Quats will be showcasing our portfolio and expertise at CPHI Japan 2025
Our team led by Saleem Shaikh, Head - International markets, APIs, Quats, Fine Chemicals, and Mr. Paul Kuad, Sales Manager, are excited to participate in CPhI Japan 2025, a gateway into the Japanese pharmaceuticals and healthcare market. Please click on the Contact Us page for their details.
CONTACT US TODAY OR DOWNLOAD
OUR COMPANY PROFILE BROCHURE
FOR FURTHER INFORMATION
“Dishman Group” is not a separate legal entity but nomenclature used in generality for Dishman Carbogen Amcis Ltd, the flagship Company, and its Indian and foreign subsidiaries, joint ventures and associate companies across the globe. All these entities are individual and separate by the law.
